The global inhaled nitric oxide delivery systems market size is calculated at USD 377.19 million in 2025 and is forecasted to reach around USD 562.47 million by 2034, accelerating at a CAGR of 4.54% from 2025 to 2034. The North America market size surpassed USD 144.32 million in 2024 and is expanding at a CAGR of 4.67% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Million), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Inhaled Nitric Oxide Delivery Systems Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Inhaled Nitric Oxide Delivery Systems Market, by Type, 2025-2034
8.1.1. Pediatric
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Adult
8.1.2.1. Market Revenue and Forecast (2022-2034)
9.1. Inhaled Nitric Oxide Delivery Systems Market, by Product, 2025-2034
9.1.1. Disposables
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. System
9.1.2.1. Market Revenue and Forecast (2022-2034)
10.1. Inhaled Nitric Oxide Delivery Systems Market, by Application, 2025-2034
10.1.1. Hypoxic Respiratory Failure (HRF)
10.1.1.1. Market Revenue and Forecast (2022-2034)
10.1.2. Acute Hypoxemic Respiratory Failure (AHRF)
10.1.2.1. Market Revenue and Forecast (2022-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2022-2034)
11.1. Inhaled Nitric Oxide Delivery Systems Market, by End-user, 2025-2034
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2022-2034)
11.1.2. Ambulatory Centers
11.1.2.1. Market Revenue and Forecast (2022-2034)
11.1.3. Clinics
11.1.3.1. Market Revenue and Forecast (2022-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2022-2034)
12.1.2. Market Revenue and Forecast, by Product (2022-2034)
12.1.3. Market Revenue and Forecast, by Application (2022-2034)
12.1.4. Market Revenue and Forecast, by End-user (2022-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2022-2034)
12.1.5.2. Market Revenue and Forecast, by Product (2022-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2022-2034)
12.1.5.4. Market Revenue and Forecast, by End-user (2022-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2022-2034)
12.1.6.2. Market Revenue and Forecast, by Product (2022-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2022-2034)
12.1.6.4. Market Revenue and Forecast, by End-user (2022-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2022-2034)
12.2.2. Market Revenue and Forecast, by Product (2022-2034)
12.2.3. Market Revenue and Forecast, by Application (2022-2034)
12.2.4. Market Revenue and Forecast, by End-user (2022-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2022-2034)
12.2.5.2. Market Revenue and Forecast, by Product (2022-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2022-2034)
12.2.5.4. Market Revenue and Forecast, by End-user (2022-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2022-2034)
12.2.6.2. Market Revenue and Forecast, by Product (2022-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2022-2034)
12.2.6.4. Market Revenue and Forecast, by End-user (2022-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2022-2034)
12.2.7.2. Market Revenue and Forecast, by Product (2022-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2022-2034)
12.2.7.4. Market Revenue and Forecast, by End-user (2022-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2022-2034)
12.2.8.2. Market Revenue and Forecast, by Product (2022-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2022-2034)
12.2.8.4. Market Revenue and Forecast, by End-user (2022-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2022-2034)
12.3.2. Market Revenue and Forecast, by Product (2022-2034)
12.3.3. Market Revenue and Forecast, by Application (2022-2034)
12.3.4. Market Revenue and Forecast, by End-user (2022-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2022-2034)
12.3.5.2. Market Revenue and Forecast, by Product (2022-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2022-2034)
12.3.5.4. Market Revenue and Forecast, by End-user (2022-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2022-2034)
12.3.6.2. Market Revenue and Forecast, by Product (2022-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2022-2034)
12.3.6.4. Market Revenue and Forecast, by End-user (2022-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2022-2034)
12.3.7.2. Market Revenue and Forecast, by Product (2022-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2022-2034)
12.3.7.4. Market Revenue and Forecast, by End-user (2022-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2022-2034)
12.3.8.2. Market Revenue and Forecast, by Product (2022-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2022-2034)
12.3.8.4. Market Revenue and Forecast, by End-user (2022-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2022-2034)
12.4.2. Market Revenue and Forecast, by Product (2022-2034)
12.4.3. Market Revenue and Forecast, by Application (2022-2034)
12.4.4. Market Revenue and Forecast, by End-user (2022-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2022-2034)
12.4.5.2. Market Revenue and Forecast, by Product (2022-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2022-2034)
12.4.5.4. Market Revenue and Forecast, by End-user (2022-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2022-2034)
12.4.6.2. Market Revenue and Forecast, by Product (2022-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2022-2034)
12.4.6.4. Market Revenue and Forecast, by End-user (2022-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2022-2034)
12.4.7.2. Market Revenue and Forecast, by Product (2022-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2022-2034)
12.4.7.4. Market Revenue and Forecast, by End-user (2022-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2022-2034)
12.4.8.2. Market Revenue and Forecast, by Product (2022-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2022-2034)
12.4.8.4. Market Revenue and Forecast, by End-user (2022-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2022-2034)
12.5.2. Market Revenue and Forecast, by Product (2022-2034)
12.5.3. Market Revenue and Forecast, by Application (2022-2034)
12.5.4. Market Revenue and Forecast, by End-user (2022-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2022-2034)
12.5.5.2. Market Revenue and Forecast, by Product (2022-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2022-2034)
12.5.5.4. Market Revenue and Forecast, by End-user (2022-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2022-2034)
12.5.6.2. Market Revenue and Forecast, by Product (2022-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2022-2034)
12.5.6.4. Market Revenue and Forecast, by End-user (2022-2034)
13.1. Mallinckrodt Pharmaceuticals
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Getinge AB
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. VERO Biotech
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Linde plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Beyond Air, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. SLE Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bellerophon Therapeutics
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Air Liquide Healthcare
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Circassia Pharmaceuticals
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. International Biomedical
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample